Personalizing the Care of Patients with Psoriatic Arthritis - Factors Influencing Treatment Selection

CMEO Multimedia Snack

Premiere Date: Wednesday, November 7, 2018

This activity offers CE credit for:

  1. Physicians (CME)
  2. Other

Credit Expiration Date: Thursday, November 7, 2019
Note: Credit Is No Longer Available


Allan Gibofsky, MD, JD, MACR, FACP, FCLM Allan Gibofsky, MD, JD, MACR, FACP, FCLM (Moderator)
Professor of Medicine
Weill Cornell Medicine
Attending Rheumatologist
Co-Director, Clinic for Inflammatory Arthritis
Hospital for Special Surgery
New York, NY

Joel M. Gelfand, MD, MSCE Joel M. Gelfand, MD, MSCE 
Professor of Dermatology and Epidemiology
Vice Chair of Clinical Research
Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Jennifer G. Kwan-Morley, MD Jennifer G. Kwan-Morley, MD 
Premier Orthopaedics
Malvern, PA

Statement of Need

Psoriatic arthritis (PsA) negatively impacts relationships, activities of daily living, work productivity, and overall quality of life. Despite the availability of effective agents for PsA, many patient with moderate-to-severe PsA are not able to achieve optimal outcomes, and often medications used to treat PsA can exacerbate other conditions.

Fortunately, the range of current treatments for PsA is expanding, with considerable ongoing research and possibilities for improved patient care. Treatment options include non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs; conventional, biological, and target agents).

Clinicians should be choosing agents based on what the phenotype of disease is, but with consideration to comorbidities. In this CME Outfitters CME Snack, expert faculty discuss and safety of agents used in treating PsA, taking patients' comorbidities into account.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Develop individualized treatment plans for patients with psoriatic arthritis that weigh the risks and benefits of newer agents.

Financial Support

Supported by educational grants from Celgene Corporation, Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.; and Novartis Pharmaceuticals Corporation.

Target Audience

Rheumatologists, dermatologists, physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with psoriatic arthritis.

Credit Information

CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluation must be completed online at (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). this website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of USF Health and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the Speakers Bureau for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc.; and Pfizer, Inc. He is a consultant for AbbVie Inc.; Celgene Corporation; Merck & Co., Inc; Pfizer Inc.; Samumed, LLC; and Sandoz. He is a stock shareholder of AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc..

Dr. Gelfand reports that he receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc.; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation, Pfizer Inc.; Ortho Dermatologics, Inc.; and Sanofi. He is a consultant for Bristol-Myers Squibb Company; Boehringer Ingelheim; GlaxoSmithKline; Janssen Biologics, Inc.; Novartis Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; and UCB Data and Safety Monitoring Board (DSMB).

Dr. Kwan-Morley has no disclosures to report.

Kate Nelson, PHD (planning committee) has no disclosures to report.

Sharon Tordoff(planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Disclosures were obtained from the USF Health staff: No disclosures to report.

CME Outfitters, LLC, USF Health, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

This document was last modified on: